Literature DB >> 8345908

The growth potential of ependymomas with varying grades of malignancy measured by the Ki-67 labelling index and mitotic index.

R Schröder1, C Ploner, R I Ernestus.   

Abstract

The prognostic significance of histopathological grade for postoperative outcome is not yet known for ependymomas. Data on proliferation kinetics of these tumors are few. In our study, the growth fraction was immunohistochemically determined by labelling cell nuclei with the monoclonal antibody Ki-67 in 24 tumors of the ependymoma group (2 malignant ependymomas grade III, 11 ependymomas grade II, 8 spinal ependymomas, and 3 subependymomas). The results were compared with the mitotic index in the same tumor areas. Both growth parameters are related to the grade of malignancy. The differences between the results of spinal ependymomas (grade I) and of intracranial tumors (grade II) were statistically significant. Malignant ependymomas had the highest values. Variable growth potentials could be demonstrated in a few tumors. A non-linear relationship between growth fraction and mitotic index was found, indicating a variable generation time in ependymomas (as in astrocytomas). Thus, with rising grade of malignancy the growth fraction increases and the generation time decreases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8345908     DOI: 10.1007/bf00258248

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  21 in total

1.  Cell kinetic analysis of brain tumors using the monoclonal antibody Ki-67: in vitro and in situ study.

Authors:  T Shiraishi
Journal:  Acta Med Okayama       Date:  1990-08       Impact factor: 0.892

2.  Ependymoma: a follow-up study of 101 cases.

Authors:  S J Mork; A C Loken
Journal:  Cancer       Date:  1977-08       Impact factor: 6.860

3.  The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology.

Authors:  P C Burger; T Shibata; P Kleihues
Journal:  Am J Surg Pathol       Date:  1986-09       Impact factor: 6.394

4.  Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study.

Authors:  D N Louis; S Edgerton; A D Thor; E T Hedley-Whyte
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

Review 5.  Intracranial tumors: response and resistance to therapeutic endeavors, 1970-1980.

Authors:  H J Bloom
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982-07       Impact factor: 7.038

6.  [KI-67 PAP stain for histologic grading of brain tumors by squash preparations].

Authors:  T Shibata; C B Ostertag; B Volk
Journal:  No To Shinkei       Date:  1989-01

7.  The monoclonal antibody Ki-67 as a marker for proliferating cells in stereotactic biopsies of brain tumours.

Authors:  C B Ostertag; B Volk; T Shibata; P Burger; P Kleihues
Journal:  Acta Neurochir (Wien)       Date:  1987       Impact factor: 2.216

8.  Proliferative potential of human brain tumours as assessed by nucleolar organizer regions (AgNORs) and Ki67-immunoreactivity.

Authors:  K H Plate; J Rüschoff; J Behnke; H D Mennel
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

9.  Intracranial ependymomas in childhood. Survival and functional results of 47 cases.

Authors:  A Pierre-Kahn; J F Hirsch; F X Roux; D Renier; C Sainte-Rose
Journal:  Childs Brain       Date:  1983

10.  Supratentorial lobar ependymomas: reports on the grading and survival periods in 80 cases, including 46 recurrences.

Authors:  D Afra; W Müller; F Slowik; O Wilcke; H Budka; L Turoczy
Journal:  Acta Neurochir (Wien)       Date:  1983       Impact factor: 2.216

View more
  7 in total

Review 1.  Immunohistochemical prognostic markers in intracranial ependymomas: systematic review and meta-analysis.

Authors:  Klara Kuncova; Ales Janda; Pavel Kasal; Josef Zamecnik
Journal:  Pathol Oncol Res       Date:  2009-03-20       Impact factor: 3.201

2.  Proliferation- and apoptosis-related proteins in intracranial ependymomas: an immunohistochemical analysis.

Authors:  M J T Verstegen; D Troost S Leenstra; H Ijlst-Keizers; D A Bosch
Journal:  J Neurooncol       Date:  2002-01       Impact factor: 4.130

3.  A clinicopathologic study of 81 patients with ependymomas and proposal of diagnostic criteria for anaplastic ependymoma.

Authors:  D M Ho; C Y Hsu; T T Wong; H Chiang
Journal:  J Neurooncol       Date:  2001-08       Impact factor: 4.130

Review 4.  Survival following treatment for intracranial ependymoma: a review.

Authors:  G Tamburrini; M D'Ercole; B L Pettorini; M Caldarelli; L Massimi; C Di Rocco
Journal:  Childs Nerv Syst       Date:  2009-04-22       Impact factor: 1.475

5.  Immunohistochemical markers for prognosis of ependymal neoplasms.

Authors:  Andrey Korshunov; Andrey Golanov; Valery Timirgaz
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

6.  Ependymoma in adults: surgery, reoperation and radiotherapy for survival.

Authors:  Dusan Vitanovics; Katalin Bálint; Zoltán Hanzély; Péter Banczerowski; Dénes Afra
Journal:  Pathol Oncol Res       Date:  2009-08-30       Impact factor: 3.201

7.  Extraneural metastasis of ependymoma in the cauda equina.

Authors:  Takahito Fujimori; Motoki Iwasaki; Yukitaka Nagamoto; Masafumi Kashii; Hironobu Sakaura; Hideki Yoshikawa
Journal:  Global Spine J       Date:  2012-11-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.